Pacira Pharmaceuticals buy Raymond James
Start price
20.12.23
/
50%
€29.60
Target price
20.12.24
€38.31
Performance (%)
-57.43%
Price
22.08.24
€12.30
Summary
This prediction is currently active. Massive losses of -57.43% have been the result for the BUY prediction by Raymond_James. This prediction currently runs until 20.12.24. The prediction end date can be changed by Raymond_James at any time. Raymond_James has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m |
---|---|---|
Pacira Pharmaceuticals | 6.957% | 6.957% |
iShares Core DAX® | 1.665% | 0.362% |
iShares Nasdaq 100 | -0.475% | -3.195% |
iShares Nikkei 225® | 2.620% | 1.174% |
iShares S&P 500 | -0.091% | -1.597% |
Comments by Raymond_James for this prediction
In the thread Pacira Pharmaceuticals diskutieren
Pacira BioSciences, Inc. (NASDAQ: PCRX) is now covered by analysts at Raymond James. They set an "outperform" rating and a $42.00 price target on the stock.
Ratings data for PCRX provided by MarketBeat
Stopped prediction by Raymond_James for Pacira Pharmaceuticals
Pacira Pharmaceuticals
Start price
Target price
Perf. (%)
€19.10
31.07.24
31.07.24
€34.20
31.07.25
31.07.25
-34.03%
22.08.24
22.08.24